URUS to Purchase Trans Ova Genetics – Cowsmo

URUS to Purchase Trans Ova Genetics

transovaPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company has entered into a definitive agreement for the sale of its wholly-owned non-healthcare subsidiary, Trans Ova Genetics, L.C. (“Trans Ova”), an industry-leading animal reproductive technologies company, to URUS, a holding company with cooperative and private ownership, for $170 million in upfront cash and up to $10 million earn-out based on the performance of Trans Ova in 2022 and 2023. Consummation of the transaction, anticipated in Q3 2022, is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

“We believe this transaction will support Precigen’s mission as a premier cell and gene therapy company laser focused on the rapid development of our top clinical assets to maximize shareholder value and potentially improve the way devastating diseases like cancer are treated,” said Helen Sabzevari, PhD, President and CEO of Precigen. “I am proud of Precigen management and the Trans Ova team for successfully leading the financial turnaround of Trans Ova operations to maximize the value of this asset over the last two years. We expect to have the capacity to pay the convertible notes upon maturity and to focus on fast regulatory paths for our healthcare portfolio.”

Rabo Securities USA, Inc. is acting as exclusive financial advisor to Precigen and Davis Polk & Wardwell LLP is providing Precigen with legal support for the transaction.

“Trans Ova will continue to Multiply Success for current and future clients with the same exceptional team, same convenient locations, and the same toolbox of services, while maintaining the standard of excellence that clients have come to expect throughout our 40 years of experience in reproductive technologies. We look forward to continuing to serve our existing clients and, upon closing of the transaction, working with URUS to add strategic resources to our company that further enhance our ability to provide leading assisted reproductive technologies.”  – David Faber, D.V.M, CEO & President Trans Ova Genetics

Precigen: Advancing Medicine with Precision™
Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit here or follow us on Twitter @PrecigenLinkedIn or YouTube.

 

Provided by Trans Ova Genetics 

Scroll to Top